PNR Ref
 PNR Req
 Blank PNRs
 Spotting
 Timeline
 Travel Tip
 Trip
 Race
 Social
 Greeting
 Poll
 Img
 PNR
 Pic
 Blog
 News
 Conf TL
 RF Club
 Convention
 Monitor
 Topic
 Bookmarks
 Rating
 Correct
 Wrong
 Stamp
 HJ
 Vote
 Pred
 @
 FM Alert
 FM Approval
 Pvt
News Super Search
 ↓ 
×
Member:
Posting Date From:
Posting Date To:
Category:
Zone:
Language:
IR Press Release:

Search
  Go  

Tamil Nadu Express - தங்களை அன்புடன் வரவேற்கிறது - Swaroop Kutti

Full Site Search
  Full Site Search  
 
Mon Nov 23 22:57:40 IST
Home
Trains
ΣChains
Atlas
PNR
Forum
Topics
Gallery
News
FAQ
Trips/Spottings
Login
Advanced Search
<<prev entry    next entry>>
News Entry# 422795
Oct 26 (18:32) Can Bharat Biotech's single-dose, 'super efficient' nasal vaccine be the game-changer? (www.businesstoday.in)
*covid-19
0 Followers
809 views

News Entry# 422795  Blog Entry# 4759274   
  Past Edits
This is a new feature showing past edits to this News Post.
Coronavirus vaccine administered through the intramuscular injection route protects the lower lungs but not the upper lung. Nasal vaccines can protect the lungs completely and stop transmission and also infection

Coronavirus vaccine administered through the intramuscular injection route protects the lower lungs but not the upper lung. Nasal vaccines can protect the lungs completely and stop transmission and also infection

...
more...


Could a new nasal COVID vaccine in the works, a partnership between Washington University in St Louis, USA, and Hyderabad-based Bharat Biotech International Ltd (BBIL), be that wonder solution which Bill Gates, in an interview to an American TV channel last week, said will check the spread of virus?

A paper in scientific journal Cell says that animal studies on nasal vaccine - single dose intranasal ChAd vaccine - protects upper and lower respiratory tracts against SARS-CoV-2. "Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission, and curtailing pandemic spread", the paper says.

It is this very vaccine that Krishna Ella, chairman and managing director of BBIL says will revolutionise Indian vaccine making capabilities and help the country leapfrog along with Europe, the US and China.

Also read: SMS, QR code-certificate, centres at schools: How India's vaccination drive may shape up

"We have completed studies on monkeys. It demonstrates 100 per cent sterilising ability. That means when a virus attacks the animal, it doesn't touch even one cell. Sterilising immunity will prevent infection and also transmission. If you want to control COVID-19, you have to stop the infection and the transmission. So while all the first generation vaccines (most coronavirus vaccines that are under various stages of development world over at the moment) can only prevent partial infection and partial transmission, nasal one will prevent both the infection and transmission", says Ella.

In an exclusive interaction with BusinessToday.In, Ella said nasal vaccine may be the best choice for India  because it will be single dose, easy to administer and super efficient. "You put one drop 0.1 ml in one nostril and 0.1 ml in the other one. You are done. Just one dose."

The entire vaccine platform developed in partnership with Washington University has been licensed to BBIL. "We have the global rights excluding the US and Europe. And in US, my partner, who is a faculty there, started Precision Medical. We will supply the Phase 1 clinical trial material from here to the US," Ella says.

According to Ella, vaccines administered through the intramuscular injection route protect the lower lungs but not the upper lung. Hence it can prevent the symptoms, but cannot prevent infection and transmission. Instead, the nasal route can protect the lungs completely and thus stop the transmission and also infection.

Also read: Coronavirus vaccine: Covaxin to be at least 60% effective, says Bharat Biotech

BBIL is getting the vaccine candidate ready for Phase I clinical trials by December. Ella says that if the government can develop a total protocol for (all phases of) clinical trials now itself, the company can get the nasal vaccine into the market by June 2021. "The production is very easy. The facility is in place already. It is a vector based vaccine. If successful, I can make more than 1 billion doses," he says.

Ella says that he is yet to discuss with the government about the advantages of having a nasal vaccine strategy in place.

Only clinical trials in human beings can say how safe and efficacious the vaccine is. Further research will also say how long the efficacy or the protective feature of the vaccine will remain. All that we know is there has been a promising start.

As the scientific paper in Cell says, the studies on monkeys "establish that immunisation with ChAd-SARS-CoV-2-S induces both neutralising antibody and antigen-specific CD8+ T cell responses. While a single intramuscular immunisation of ChAd-SARS-CoV-2-S confers protection against SARS-CoV-2 infection and inflammation in the lungs, intranasal delivery of ChAd-SARS-CoV-2-S induces mucosal immunity, provides superior protection, and possibly promotes sterilising immunity, at least in mice." The paper recommended further studies as "intranasal delivery of ChAd-SARS-CoV-2-S is a promising platform for preventing SARS-CoV-2 infection, disease, and upper airway transmission, and thus warrants clinical evaluation in humans".

Incidentally, Pune based Serum Institute of India, world's largest vaccine maker by volume, is also working on a nasal COVID-19 vaccine, through using a different technology.

Also read: Coronavirus vaccine: Centre earmarks Rs 50,000 crore for vaccination of 1.3 billion people

LATEST

Must Read

TECH NEWS
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy